Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells

28 Apr 2018

Abstract excerpt

CRISPR/Cas9-mediated programmed cell death protein 1 (PD-1) disruption in chimeric antigen receptor (CAR) T cells could be an appealing choice to improve the therapeutic efficacy of CAR T cells in an immunosuppressive tumor microenvironment. In most of the reported cases, Cas9 was delivered into T cells by way of electroporation with RNA or protein. However, transient expression of Cas9 by transfection with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29706119
DOI: 10.1089/hum.2017.234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T CellsPMID 29706119Read ↗

CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitroSemantic proximity Read ↗

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.Semantic proximity Read ↗

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapySemantic proximity Read ↗

Plasmid- or Ribonucleoprotein-Mediated CRISPR/Cas Gene Editing in Primary Murine T Cells.Semantic proximity Read ↗

High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNASemantic proximity Read ↗

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read ↗

A carrier-free multiplexed gene editing system applicable for suspension cellsSemantic proximity Read ↗

Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technologySemantic proximity Read ↗

Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cellsSemantic proximity Read ↗

Elucidation of CRISPR-Cas9 Application in Novel Cellular Immunotherapy.Semantic proximity Read ↗

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read ↗

Cas9‐Cleavage Sequences in Size‐Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.